When drug val­ue as­sess­ment meets re­al-world ev­i­dence: ICER en­lists Ae­tion in pric­ing eval­u­a­tion

In a union of two of the hottest trends in the US bio­phar­ma world, ICER is team­ing up with a high-pro­file com­pa­ny to in­te­grate re­al-world ev­i­dence in their as­sess­ment of treat­ment val­ue.

The drug pric­ing watch­dog — for­mal­ly the In­sti­tute for Clin­i­cal and Eco­nom­ic Re­view — said it will uti­lize Ae­tion’s ev­i­dence plat­form in “se­lect up­com­ing as­sess­ments” and their new 24-month re-eval­u­a­tions of drugs grant­ed ac­cel­er­at­ed ap­proval by the FDA.

Even though ICER doesn’t play an of­fi­cial role in set­ting drug prices, its ver­dicts on whether treat­ments are cost-ef­fec­tive are in­creas­ing­ly shap­ing pay­er at­ti­tude and con­sumer per­cep­tion, as well as, gen­er­al dis­course as the heat­ed de­bate around US drug prices rages on.

Car­olyn Mag­ill

Led by Unit­ed­Health vet Car­olyn Mag­ill, Ae­tion de­rives much of its da­ta from in­sur­ance claims, but it al­so works with elec­tron­ic health records, reg­istries and clin­i­cal tri­als. The FDA and Brigham and Women’s Hos­pi­tal have a pact in place with the com­pa­ny to try pre­dict­ing the re­sults of ran­dom­ized clin­i­cal tri­als in a pi­lot project in­volv­ing sev­en stud­ies.

Scott Got­tlieb, who pushed the in­dus­try to try new things with RWE dur­ing his tenure as FDA com­mis­sion­er, joined Ae­tion’s board a few months af­ter leav­ing the agency.

David Whitrap

For its part, ICER has com­mit­ted to ex­pand­ing its RWE use, not on­ly us­ing ex­ist­ing sources such as man­u­fac­tur­ers and pa­tient or­ga­ni­za­tions but ex­plor­ing ways to gen­er­ate da­ta that can com­ple­ment pub­lished sources. The deal with Ae­tion al­lows them to do it at greater scale, David Whitrap, ICER’s VP of com­mu­ni­ca­tions and out­reach, told End­points News.

Where­as RWE can come in handy for com­par­isons to ex­ist­ing treat­ments and the nat­ur­al trend of cer­tain con­di­tions (such as sick­le cell dis­ease, where ICER is con­duct­ing a re­view of ther­a­pies with Ae­tion’s help), their re­la­tion­ship will be most use­ful in the new process they are pi­lot­ing: re-eval­u­at­ing treat­ments af­ter they’ve been on the mar­ket for sev­er­al years.

“Ran­dom­ized clin­i­cal tri­als re­main the gold stan­dard for de­vel­op­ing un­bi­ased ev­i­dence, but as the FDA is in­creas­ing­ly ap­prov­ing treat­ments based on thin­ner clin­i­cal tri­al da­ta, the en­tire health in­dus­try will need to fill larg­er knowl­edge gaps about how well a new drug ac­tu­al­ly works,” he said. “And RWE is one way to do so.”

Once fu­ri­ous over No­var­tis’ da­ta ma­nip­u­la­tion scan­dal, the FDA now says it’s noth­ing they need to take ac­tion on

Back in the BP era — Before Pandemic — the FDA ripped Novartis for its decision to keep the agency in the dark about manipulated data used in its application for Zolgensma while its marketing application for the gene therapy was under review.

Civil and criminal sanctions were being discussed, the agency noted in a rare broadside at one of the world’s largest pharma companies. Notable lawmakers cheered the angry regulators on, urging the FDA to make an example of Novartis, which fielded Zolgensma at $2.1 million — the current record for a one-off therapy.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,000+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: GSK, Am­gen tai­lor R&D work to fit the coro­n­avirus age; Doud­na's ge­nomics crew launch­es di­ag­nos­tic lab

You can add Amgen and GSK to the list of deep-pocket drug R&D players who are tailoring their pipeline work to fit a new age of coronavirus.

Following in the footsteps of a lineup of big players like Eli Lilly — which has suspended patient recruitment for drug studies — Amgen and GSK have opted to take a more tailored approach. Amgen is intent on circling the wagons around key studies that are already fully enrolled, and GSK has the red light on new studies while the pandemic plays out.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,000+ biopharma pros reading Endpoints daily — and it's free.

It is 'kind of a proven tech­nol­o­gy': Hep B vac­cine mak­er joins glob­al hunt for coro­n­avirus vac­cine

Using lab-grown proteins that are engineered to mimic the architecture of viruses to induce an immune response, VBI Vaccines is joining the hunt for a coronavirus vaccine — harnessing technology that has initially been proved safe in early trials as a prophylactic for cytomegalovirus (CMV) infection.

Unlike the raft of the companies in the Covid-19 vaccine race — including Moderna, CureVac and J&J — VBI is taking a pan-coronavirus approach, by developing a vaccine that will encompass Covid-19, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS).

In a stun­ning set­back, Amarin los­es big patent fight over Vas­cepa IP. And its high-fly­ing stock crash­es to earth

Amarin’s shares $AMRN were blitzed Monday evening, losing billions in value as reports spread that the company had lost its high-profile effort to keep its Vascepa patents protected from generic drugmakers.

Amarin had been fighting to keep key patents under lock and key — and away from generic rivals — for another 10 years, but District Court Judge Miranda Du in Las Vegas ruled against the biotech. She ruled that:
(A)ll the Asserted Claims are invalid as obvious under 35 U.S.C.§ 103. Thus, the Court finds in favor of Defendants on Plaintiff’s remaining infringementclaim, and in their favor on their counterclaims asserting the invalidity of the AssertedClaims under 35 U.S.C. § 103.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,000+ biopharma pros reading Endpoints daily — and it's free.

Can a pair of top AveX­is alum­ni steer a new gene ther­a­py up­start to R&D glo­ry? 3 VCs bet $60M on it

VCs love few things more than a proven executive team when it comes to launching a new company. And now a group of A-listers has turned to a pair of top execs out of AveXis to steer the latest gene therapy player into the clinic.

The biotech is Waltham, MA-based Affinia and the two execs are Sean Nolan and Rick Modi — the former CEO and CBO respectively of AveXis, the gene therapy pioneer that fetched $8.7 billion in a sale to Novartis. Nolan has now taken the chairman’s role at Affinia while Modi moves up to the CEO post at the company.

Un­de­terred by a pan­dem­ic, Gilde Health­care rais­es their largest fund yet

When Pieter van der Meer started raising the capital for Gilde Healthcare’s fifth fund in the waning months of 2019, he had his eyes on a different chain of events that could change the healthcare system and perhaps even play to his firm’s advantage: The US presidential election.

Since raising their third fund in 2011, the 34-year-old Dutch firm had focused on value-based care. They chose late-stage biotechs that came up with new devices and delivery systems for de-risked established compounds, and when they chose preclinical biotechs, they spoke with potential pharma partners, payers and regulators to ask where and at what prices the drug made sense. As the Democratic primary became a contest over how to lower healthcare costs, it looked like a strategy that could pay off.

Covid-19 roundup: J&J, BAR­DA set ear­ly 2021 fin­ish line for $1B vac­cine race; FDA al­lows emer­gency drug use, ahead of piv­otal da­ta

J&J has zeroed in on a Covid-19 vaccine candidate that it hopes to begin testing in humans by September this year — with the extraordinary goal of getting it ready for emergency use in early 2021. And together with BARDA, it’s committing $1 billion to make it happen.

That kind of accelerated timeline would fall on the fast side of NIAID director Anthony Fauci’s well-publicized prediction that it would be another 12 to 18 months before a vaccine can be available for public use. A Phase I trial of Moderna’s mRNA vaccine began two weeks ago, and both the biotech and fellow mRNA player CureVac have discussed similar, if not even faster, timelines for emergency use among healthcare workers.

Mene Pangalos via YouTube

As­traZeneca says its block­buster Farx­i­ga proved to be a game-chang­er in CKD — wrap­ping PhI­II ear­ly

If the FDA can still hold up its end of the bargain, AstraZeneca is already on a short path to scooping up a cutting-edge win with a likely approval for their SGLT2 drug Farxiga in cutting the risk of heart failure. Now the pharma giant says it can point to solid evidence that the drug — initially restricted to diabetes — also works for chronic kidney disease, potentially adding a blockbuster indication for the franchise.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,000+ biopharma pros reading Endpoints daily — and it's free.

Just in time to as­sure a de­ci­sion be­fore CVR dead­line, Bris­tol My­ers Squibb files NDA for Cel­gene/blue­bird CAR-T

A new CAR-T therapy may be coming. And maybe $9 per share for Celgene investors, too.

Bristol Myers Squibb announced they submitted an NDA for the multiple myeloma “ide-cel” CAR-T therapy Celgene developed in partnership with bluebird. The therapy is one of the three that has to be approved to unlock the BMS-Celgene contingent value agreement that would give shareholders of the absorbed NJ company $9 per share. The first, ozanimod, was approved last week. The second, a CAR-T treatment for non-Hodgkin’s lymphoma called liso-cel, was submitted to the FDA in December.